12:00 AM
Oct 13, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Fibrin Pad: Interim Phase II data

Interim data from the first cohort of 90 patients undergoing surgery in a U.S. Phase II trial showed that Fibrin Pad was superior to Surgicel on the primary endpoint of the proportion of patients experiencing hemostatic success at 4...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >